Rapid Micro Biosystems (RPID) Expected to Announce Quarterly Earnings on Friday

Rapid Micro Biosystems (NASDAQ:RPID - Get Free Report) will likely be posting its Q2 2025 quarterly earnings results before the market opens on Friday, August 1st. Analysts expect Rapid Micro Biosystems to post earnings of ($0.26) per share and revenue of $7.10 million for the quarter. Rapid Micro Biosystems has set its FY 2025 guidance at EPS.

Rapid Micro Biosystems (NASDAQ:RPID - Get Free Report) last released its quarterly earnings data on Friday, May 9th. The company reported ($0.26) EPS for the quarter, topping analysts' consensus estimates of ($0.27) by $0.01. The business had revenue of $7.21 million during the quarter, compared to the consensus estimate of $6.63 million. Rapid Micro Biosystems had a negative return on equity of 56.07% and a negative net margin of 151.22%. On average, analysts expect Rapid Micro Biosystems to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Rapid Micro Biosystems Stock Up 1.7%

Shares of RPID stock traded up $0.07 on Monday, reaching $4.15. 98,696 shares of the stock were exchanged, compared to its average volume of 82,199. The stock has a market cap of $181.89 million, a P/E ratio of -4.03 and a beta of 1.32. The firm has a 50 day moving average of $3.49 and a two-hundred day moving average of $2.80. Rapid Micro Biosystems has a 1-year low of $0.66 and a 1-year high of $4.50.

Insider Activity at Rapid Micro Biosystems

In related news, CEO Robert G. Jr. Spignesi sold 11,881 shares of the company's stock in a transaction on Monday, July 14th. The shares were sold at an average price of $3.32, for a total transaction of $39,444.92. Following the completion of the sale, the chief executive officer directly owned 970,550 shares of the company's stock, valued at approximately $3,222,226. This represents a 1.21% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last three months, insiders sold 57,443 shares of company stock worth $195,952. Corporate insiders own 29.96% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Lake Street Capital began coverage on Rapid Micro Biosystems in a report on Monday. They set a "buy" rating and a $8.00 price objective for the company.

About Rapid Micro Biosystems

Rapid Micro Biosystems, Inc, a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in the United States, Germany, Switzerland, Japan, and internationally. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and customer support and validation services.